Telix Pharmaceuticals (NASDAQ:TLX) Rating Increased to Moderate Buy at Royal Bank Of Canada

Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals (NASDAQ:TLX) from a hold rating to a moderate buy rating in a report issued on Monday,Zacks reports.

TLX has been the topic of a number of other reports. Wedbush reiterated an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Monday, September 14th. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Tuesday, September 15th. Finally, Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $20.40.

Telix Pharmaceuticals Stock Performance

Shares of NASDAQ:TLX opened at $11.31 on Monday. The business’s 50 day moving average is $11.30 and its 200 day moving average is $10.38. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $13.11. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16.

Institutional Trading of Telix Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its holdings in Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares during the period. XY Capital Ltd purchased a new stake in Telix Pharmaceuticals in the first quarter worth $120,000. Lazard Asset Management LLC lifted its stake in Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after acquiring an additional 39,400 shares during the period. Private Advisor Group LLC increased its position in Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares during the period. Finally, Hennion & Walsh Asset Management Inc. purchased a new stake in shares of Telix Pharmaceuticals in the 2nd quarter worth about $1,731,000.

Telix Pharmaceuticals News Summary

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Telix and ITM plan to combine their complementary businesses to create a larger radiopharmaceutical company, strengthening Telix’s access to radioisotope production, development capabilities and international markets. Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
• Positive Sentiment: The deal is intended to improve the security and scale of Telix’s isotope supply, potentially supporting future product launches, manufacturing growth and long-term revenue expansion. Telix and ITM merge to create a radiopharmaceutical powerhouse
• Positive Sentiment: Management’s merger presentation and call emphasized the strategic rationale for building a scaled radiopharmaceutical leader, which could create synergies and broaden Telix’s competitive position if integration is successful. Telix Pharmaceuticals M&A Call Transcript

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.